Caliway Biopharmaceuticals C, TW0006919004

Caliway Biopharmaceuticals stock: CBL-514 targets Phase 3

Published on 10/30/2026 at 09:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Caliway Biopharmaceuticals stock is tied to a pipeline led by the investigational drug CBL-514. The company is expanding late-stage trials.

Pipeline and financing priorities

CBL-514 is Caliway's lead investigational drug for nonsurgical fat reduction.
The company plans global pivotal Phase 3 studies and is pursuing additional indications.
Caliway raised USD 206 million in its 2024 IPO to support clinical development and partnerships.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals is advancing its clinical pipeline around CBL-514, an investigational small-molecule drug designed for nonsurgical fat reduction. In an interview dated March 1, 2025, BioSpectrum Asia reported that the company was preparing pivotal Phase 3 studies and seeking regulatory progress in the United States and Canada.

The interview with Chief Executive Officer and Chief R&D Officer Vivian Ling also described CBL-514 as a potential alternative to liposuction for localized fat reduction. The compound is designed to selectively induce adipocyte apoptosis, or the programmed death of fat cells. The candidate remains in clinical development and is not an approved medicine.

Late-stage development remains central

According to BioSpectrum Asia, Caliway intended to direct a significant share of its financing toward global multicenter Phase 3 studies for CBL-514. The company also highlighted development of additional indications, including Dercum's disease and weight rebound prevention.

The interview said Caliway raised USD 206 million, or TWD 6.4 billion, in its October 2024 IPO. Management described the funds as supporting research and development, international partnerships, licensing discussions and commercial preparation. Those plans leave regulatory execution, recruitment and future clinical results as key factors for investors.

Pipeline breadth adds optionality

Beyond CBL-514, the company discussed early-stage programs for hyperpigmentation, skin aging and post-weight-loss fat accumulation. The breadth may expand Caliway's potential markets, but it also increases the number of development and regulatory milestones that must be financed and delivered.